Novartis AG
Multinational pharmaceutical corporation
Basel, Switzerland
Data Confidence: 72% · Sources: 1 · Last Updated: Sep 18, 2026
- Net Worth ▲
- Undisclosed — estimated significant wealth
- Reach ▲
- 100.0M people
- Power ▲
- As the eighth largest pharmaceutical corporation by revenue in 2024, Novartis controls global manufacturing of major drugs including Clozaril, Diovan, Gleevec, and Exjade.
- Influence ▲
- Novartis influences pharmaceutical markets through landmark drug transactions, such as selling Voltaren to GlaxoSmithKline in 2015, and producing methylphenidate (Ritalin) via Sandoz.
- Network ▲
- Novartis stems from the historic 1996 merger of Ciba-Geigy and Sandoz, and maintains business relationships with major industry peers like GlaxoSmithKline.
- Legacy ▲
- Created through what was considered the largest corporate merger in history in 1996, Novartis pioneered key global treatments such as imatinib mesylate (Gleevec/Glivec) and letrozole (Femara).
- Trajectory ▲
- Rising ↑ — first assessment on record.
About
Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, Switzerland, and was the eighth largest pharmaceutical company globally by revenue in 2024. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz, which was considered the largest corporate merger in history at that time. Novartis manufactures a wide range of well-known medications, including clozapine (Clozaril), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), and methylphenidate (Ritalin).
Known For
Manufacturing major pharmaceutical products such as Gleevec, Diovan, and Ritalin, and being formed by the historic 1996 merger of Ciba-Geigy and Sandoz.
Connections
Other Ties
Similar Profiles
ChevroletTop ContinentalFlagship automobile manufacturing division of General Motors
Francesco StaraceTop ContinentalFormer CEO and General Manager of Enel GroupSources
- Wikipediacorroborated